semaglutide new england journal of medicine π¨BREAKING: for MASH: A Step Forward in Metabolic Liver Disease Phase 3 data just released (NEJM 2025): In 800 patients with biopsy-confirmed MASH and fibrosis stage 2β3, semaglutide 2.4 mg weekly Semaglutide in Early Type 1
Description
This breaks down the GLP-1 reward signaling mechanism behind that pattern and where the honest limits of the evidence sit.
Most patients on semaglutide therapy begin noticing appetite changes within days, with measurable weight loss typically appearing in the first 4 weeks of treatment
(Commercial Product)
| 23andMe plans to launch a GLP-1 weight loss telehealth membership through its Lemonaid Health platform by the end of the month.
Free weight loss consultations available.
